Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VTX-27 是蛋白激酶 C θ (PKC θ) 的一种选择性抑制剂,对 PKC θ 和 PKC δ 的 Ki 值分别为 0.08 nM 和 16 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,260 | 现货 | ||
2 mg | ¥ 1,870 | 现货 | ||
5 mg | ¥ 3,710 | 现货 | ||
10 mg | ¥ 5,330 | 现货 | ||
25 mg | ¥ 8,280 | 现货 | ||
50 mg | ¥ 11,170 | 现货 | ||
100 mg | ¥ 14,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,430 | 现货 |
产品描述 | VTX-27 is a selective inhibitor of protein kinase C θ (PKC θ) (Kis: 0.08 nM and 16 nM for PKC θ and PKC δ). |
靶点活性 | PKCα:356 nM (ki), PKCδ:16 nM (ki), PKCθ:0.08 nM (ki) |
体外活性 | It has also been found that VTX-27 has good selectivity to other PKC family members, especially the classic isoforms (except for PKCβI, >1000 times, 200 times) and atypical isoforms (>10000 times). As expected, it is more challenging to obtain selectivity for more closely related novel PKC family members, which is 200 times more selective than PKCδ. |
体内活性 | VTX-27 shows the best PK profile with low clearance (7 mL/min/kg), good oral bioavailability (65%), and long half-life (4.7 h). A single dose of VTX-27 is administered orally at 6.25, 12.5, 25, and 50 mg/kg (e.g., at 25 mg/kg Cmax concentration 700 ng/mL) and demonstrates potent dose-dependent inhibition of IL-2 production. |
分子量 | 418.9 |
分子式 | C20H24ClFN6O |
CAS No. | 1321924-70-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (298.40 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3872 mL | 11.936 mL | 23.872 mL | 59.6801 mL |
5 mM | 0.4774 mL | 2.3872 mL | 4.7744 mL | 11.936 mL | |
10 mM | 0.2387 mL | 1.1936 mL | 2.3872 mL | 5.968 mL | |
20 mM | 0.1194 mL | 0.5968 mL | 1.1936 mL | 2.984 mL | |
50 mM | 0.0477 mL | 0.2387 mL | 0.4774 mL | 1.1936 mL | |
100 mM | 0.0239 mL | 0.1194 mL | 0.2387 mL | 0.5968 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
VTX-27 1321924-70-2 Chromatin/Epigenetic Cytoskeletal Signaling PKC Inhibitor VTX 27 Protein kinase C inhibit VTX27 inhibitor